Products
Online Inquiry
Dovitinib (TKI-258) Dilactic acid
Cat. No.:
OB0225WX-2514
Appearance:
Solid
Purity:
≥95%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
Dovitinib (TKI-258) Dilactic acid is the dilactate salt of a multi-kinase RTK inhibitor with high potency against Class III (FLT3/c-Kit), Class IV (FGFR), and Class V (VEGFR) receptors.
Synonym:
852433-84-2; Dovitinib dilactic acid; Dovitinib Dilactic acid (TKI258 Dilactic acid); CHIR-258 Dilactic acid; dovitinib; bis(lactic acid); Dovitinib Dilacticacid; TKI258 Dilactic acid; 4-amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one bis(2-hydroxypropanoate)
CAS No.:
852433-84-2
Compound CID:
135985126
Formula:
C27H33FN6O7
Formula Weight:
572.59
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Dovitinib (TKI-258) Dilactic acid is applied in oncology research as a multi-kinase inhibitor to study the concurrent blockage of VEGFR and FGFR signaling in the inhibition of tumor angiogenesis.
Library Information
Target:
c-Kit; FGFR; FLT3; PDGFR; VEGFR
Receptor:
c-Kit; FGFR; FLT3; PDGFR; VEGFR
Pathways:
Angiogenesis
Plate Number:
L6700-04
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
90 mg/mL; 157.18 mM
Water Max Solubility:
70 mg/mL; 122.25 mM
ALogP:
-2.038
HBA_Count:
4
HBD_Count:
5
Rotatable Bond:
4
